Abstract
Background: Change in tumor size and serum carbohydrate antigen (CA) 19-9 are commonly reported metrics used to assess response to neoadjuvant therapy (NAT) in pancreatic ductal adenocarcinoma (PDAC). We evaluated the impact of the percentual tumor size reduction (TSR) and CA 19-9 on resectability and response to neoadjuvant FOLFIRINOX.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
